Consumer Staples

CV Sciences Reports Third-Quarter 2026 Revenue of $3.0 Million

CV Sciences reported third-quarter 2026 revenue of $3.0 million, while gross margin reached 50.0% and adjusted EBITDA was positive at $32,000.

Published:
Reading Time
3 min

CV Sciences, Inc. (OTCQB:CVSI) reported financial results for the quarter ended September 30, 2026, including revenue of $3.0 million, a gross margin of 50.0% and positive adjusted EBITDA of $32,000. The company also reported lower operating expenses and continued regulatory monitoring related to hemp-derived cannabinoid products.

#Revenue and profitability

Third-quarter revenue was $3.0 million, compared with $3.3 million in the third quarter of 2025 and $3.0 million in the second quarter of 2026. CV Sciences said the year-on-year decline reflected lower sales volume linked to restrictive regulations at the federal level and in certain states, along with decreases in average sales prices.

The number of units sold fell by 4.7% compared with the third quarter of 2025. Gross margin was 50.0%, versus 48.5% in the prior-year quarter and 48.6% in the second quarter of 2026.

Operating expenses were $1.6 million, down from $1.8 million in the third quarter of 2025 and $1.7 million in the second quarter of 2026, excluding the benefit from the gain on legal settlement. The company recorded operating income of $0.4 million, compared with an operating loss of $0.3 million in the third quarter of 2025. CV Sciences attributed most of the improvement to a $0.5 million gain on legal settlement and lower operating expenses.

Adjusted EBITDA, which CV Sciences identifies as a non-GAAP measure, was positive at $32,000. The company reported adjusted EBITDA losses of $118,000 in the third quarter of 2025 and $132,000 in the second quarter of 2026.

#Cash and working capital

CV Sciences reported a cash balance of $0.3 million at quarter and year end. Working capital was $0.7 million at quarter end, compared with $0.1 million at year end.

#Product portfolio and regulatory update

Products launched since January 1, 2023 accounted for 48% of third-quarter net revenue. The company said it launched 53 new products during that period.

During the quarter, CV Sciences expanded its +PlusHLTH™ portfolio with personalised wellness solutions designed to support healthy ageing. The company also continued monitoring potential updates to the implementation of restrictive federal provisions for hemp-derived cannabinoid products, which are currently scheduled to be in effect on December 11, 2026.

Joseph Dowling, Chief Executive Officer of CV Sciences, said the company remained focused on its established brands, broader science-based wellness categories, disciplined capital allocation and strategic opportunities. He also referred to ongoing regulatory challenges and pressure on revenue.

#Company background and results call

CV Sciences develops hemp extracts and other science-backed, natural ingredients and products. Its brands include +PlusCBD™, +PlusHLTH™ and Cultured Foods™, and the company also owns Elevated Softgels. Its products are sold through B2B and B2C channels.

The company scheduled a conference call and webcast for November 12, 2026, at 4:30 pm EDT/1:30 pm PDT to discuss the results. A telephone replay was scheduled to become available approximately three hours after the call concluded and remain available through Thursday, November 26, 2026.

#Key Takeaways

  • Third-quarter 2026 revenue was $3.0 million, compared with $3.3 million in the third quarter of 2025.
  • Gross margin was 50.0%, while operating expenses were $1.6 million.
  • Adjusted EBITDA was positive at $32,000, compared with adjusted EBITDA losses of $118,000 and $132,000 in the stated comparison periods.
  • Products launched since January 1, 2023 contributed 48% of third-quarter net revenue, with 53 new products launched during that period.
  • CV Sciences continued monitoring federal provisions for hemp-derived cannabinoid products scheduled to be in effect on December 11, 2026.

Original source: Read original article

Frequently Asked Questions